Images List Premium Download Classic

Vaccine Adjuvant

Vaccine Adjuvant-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Novel compounds
June 08, 2017 - N°20170158724

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous ...
Vaccine adjuvants
Purdue Research Foundation
May 11, 2017 - N°20170128567

The present invention provides a new adjuvant for administering vaccines.
Novel compounds
Purdue Research Foundation
March 23, 2017 - N°20170080085

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds ...
Vaccine Adjuvant Patent Pack
Download + patent application PDFs
Vaccine Adjuvant Patent Applications
Download + Vaccine Adjuvant-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine Adjuvant-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Vaccine adjuvants for cytomegalovirus prevention and treatment
The Johns Hopkins University
January 26, 2017 - N°20170021014

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for treating human cytomegalovirus using bacterial cell wall components mdp and tri-dap as vaccine adjuvants. In specific embodiments, the present invention provides a pharmaceutical composition comprising a human cytomegalovirus vaccine and a nod1 activator and/or a nod2 activator. In particular ...
Plasmid, method and kit thereof for producing heat labile enterotoxin b-subunit
Agricultural Technology Research Institute
January 05, 2017 - N°20170002045

The present invention provides a plasmid, method and kit for producing heat labile enterotoxin b-subunit based on a bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin b-subunit in the ...
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
Merck Sharp & Dohme Corp
December 15, 2016 - N°20160361411

The instant invention provides for novel lipid nanoparticle (lnp) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide lnp formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (...
Vaccine Adjuvant Patent Pack
Download + patent application PDFs
Vaccine Adjuvant Patent Applications
Download + Vaccine Adjuvant-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine Adjuvant-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
National Research Council Canada
October 06, 2016 - N°20160287698

Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Use of rapamycin as vaccine adjuvant and preparation method therefor
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
September 29, 2016 - N°20160279236

Disclosed are an immuno-enhancer composition, a use of same as a vaccine adjuvant, and a preparation method therefor. The composition comprises rapamycin and a toll-like receptor agonist-type adjuvant.
6-amino-purin-8-one compounds
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
August 11, 2016 - N°20160228445

Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases ...
1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation ...
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
July 14, 2016 - N°20160200758

The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer.
Lipidated immune response modifier compound compositions, formulations, and methods
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
June 23, 2016 - N°20160175433

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxyl}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
An oil-in-water emulsion containing no surfactant and use thereof
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
June 23, 2016 - N°20160175432

The present invention discloses an oil-in-water emulsion containing no surfactant, which comprises a metabolizable oil phase, an aqueous phase and oil-water amphipathic solid particles dispersed in the aqueous phase and having biocompatibility, wherein the oil phase comprises squalene or/and tocol; the aqueous phase is any one selected from the group consisting of purified water, water for injection, glycerine aqueous ...
Vaccine system for vaccine adjuvant
Vaxform Llc
May 19, 2016 - N°20160136266

The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced th1 response. The present invention also provides methods of making those compositions and administration of the improved adjuvant compositions
Vaccine Adjuvant Patent Pack
Download + patent application PDFs
Vaccine Adjuvant Patent Applications
Download + Vaccine Adjuvant-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine Adjuvant-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for producing beta-hematin crystal comprising step of heating
Nippon Zenyaku Kogyo Co., Ltd.
May 05, 2016 - N°20160122378

This invention provides a method of preparing a β-hematin crystal comprising a step of heating, the β-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the β-hematin crystal. The β-hematin crystal has a needle-like morphology, it has an average particle size of 0. 6 to 1. 2 μm, and it exhibits ...
Pyrazolopyrimidine compounds
Nippon Zenyaku Kogyo Co., Ltd.
January 28, 2016 - N°20160022686

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be ...
Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
Spring Bank Pharmaceuticals, Inc.
December 31, 2015 - N°20150374816

The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer ...
Synthetic tlr4 and tlr7 ligands as vaccine adjuvants
Icahn School Of Medicine At Mount Sinai
December 24, 2015 - N°20150366962

This disclosure relates to compositions and methods useful to augment an immune response and methods and compositions for inducing immunogenicity to influenza antigens.
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
Board Of Regents, The University Of Texas System
December 03, 2015 - N°20150343056

Cyclic-gmp-amp synthase (cgas) and cyclic-gmp-amp (cgamp), including 2′3-cgamp, 2′2-cgamp, 3′2′-cgamp and 3′3′-gamp, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.
Toll-like receptor 2-agonistic lipopeptides, and method of making the same
University Of Kansas
November 26, 2015 - N°20150337009

The present disclosure is directed to a novel class of toll-like receptor 2-agonistic (tlr2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, tlr2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most successful medical interventions against infectious disease.
Novel compounds
University Of Kansas
October 22, 2015 - N°20150299204

Wherein r1 is n-c3-6alkyl; r2 is hydrogen or methyl; r3 is hydrogen or c1-6alkyl, and m is an integer having a value of 1 to 4; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example ...
Novel compounds
University Of Kansas
October 08, 2015 - N°20150284396

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds ...
Loading